The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2749-2758

  Jassem, Jacek ^a   Carroll, Christopher ^b   Ward, Sue E ^b   Simpson, Emma ^b   Hind, Daniel ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adult; Anthracyclines; Breast neoplasms; Female; Neoplasms metastes; Quality of life; Review; Survival; Taxoids

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ADVANCED CANCER; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; META ANALYSIS; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY DYSFUNCTION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; TAXOIDS; TREATMENT OUTCOME;

EID: 70350005423     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.035     Document Type: Article

References (20)

1. National Institute for Health and Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. Full Guideline. London: NICE; 2009.
2. Esteva F.J., Valero V., Pusztai L., et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6 (2001) 133-146
3. Cortes J., and Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist 12 (2007) 271-280
4. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 (2005) 20-29
5. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer 8 Suppl. 2 (2008) S61-S70
6. Perez E.A. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114 (2009) 195-201
7. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer V.2.08. 2008.
8. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18 (2007) 215-225
9. NHS CRD. NHS centre for reviews and dissemination. Report 4: undertaking systematic reviews of research on effectiveness; CRD's guidance for those carrying out or commissioning reviews. University of York: New York; 2009.
10. Downs S.H., and Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Commun Health 52 (1998) 377-378
11. Parmar M.K.B., Torri V., and Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
12. National Cancer Institute. Common toxicity criteria manual. Cancer Therapy Evaluation Program. NCI; 1999.
13. Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme. Lancaster; 2006.
14. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
15. Keller A., et al. Randomized Phase III trial of Peglylated Liposomal Doxorubicin versus Vinorelbine or Mitomycin C plus Vinblastin in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 (2004) 3893-3901
16. Delaloge S, et al. A multistep randomized phase II/III trial comparing oxaliplatin (OXA) + 5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): final results. In ASCO Annual Meeting Proceedings; 2004. p. 23-41.
17. Verma S., Wong N.S., Trudeau M., et al. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol 30 (2007) 297-302
18. Martin M., Ruiz A., Munoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8 (2007) 219-225
19. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the Quorom Statement. Lancet 354 (1999) 1896-1900
20. Raff J.P., Rajdev L., Malik U., et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4 (2004) 420-427